Gewinn- und Verlustrechnung von Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) reached a new 52-week high on Tuesday. The company traded as high as $18.22 and last traded at $15.5170, with a volume of 2024663 shares. The stock had previously closed at $14.98. Analyst Upgrades and Downgrades Several analysts recently issued reports on DNA shares. Zacks Research

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) saw unusually-strong trading volume on Monday. Approximately 2,686,466 shares changed hands during mid-day trading, an increase of 111% from the previous session's volume of 1,273,783 shares. The stock last traded at $14.8780 and had previously closed at $12.35. Wall Street Analysts Forecast Growth DNA has been

Ginkgo Bioworks and Eli Lilly announced a partnership last month focused on AI drug discovery. The stock has skyrocketed since the partnership was announced.

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.

Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel

In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data. Ginkgo Datapoints will provide discovery data generation services, including small mol.

BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it has been awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health's (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. Ginkgo will serve as a subcontractor to prime contractor Waterfall Scientific, Inc. on ESCALATOR (Engineering a Small-scale, Continuous-flow manufacturing Apparatus to Launch A Transformational Overhaul for RNA medicines), a mul.